An assay of high sensitivity and specificity for detection of residual malignant cells in remission bone marrow from patients with acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL) has been developed. The assay combined an immunoselection step with immunoglobulin gene rearrangement analysis by high specific-activity DNA Probes. In experimental conditions, less than one contaminating tumor cell out of 1000 bone marrow cells was detected. A bone marrow contamination was detected in morphologically negative bone marrow specimens from two intermediate-grate non-Hodgkin's lymphoma patients. This method can be of value in determining a true remission status in high-risk ALL and NHL patients.
|Number of pages||10|
|Journal||Annals of the New York Academy of Sciences|
|Publication status||Published - 1987|
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)